
<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://proteopedia.org/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Yunlong+Zhao</id>
	<title>Proteopedia - User contributions [en]</title>
	<link rel="self" type="application/atom+xml" href="https://proteopedia.org/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Yunlong+Zhao"/>
	<link rel="alternate" type="text/html" href="https://proteopedia.org/Special:Contributions/Yunlong_Zhao"/>
	<updated>2026-09-21T11:13:42Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://proteopedia.org/index.php?title=CBI_Molecules&amp;diff=1926545</id>
		<title>CBI Molecules</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=CBI_Molecules&amp;diff=1926545"/>
		<updated>2014-05-12T14:03:01Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;These are molecules under study by members of the [http://www.umass.edu/cbi/ University of Massachusetts Amherst Chemistry-Biology Interface Program].&lt;br /&gt;
Many of the  molecules we study are featured at the [http://www.molecularplayground.org/ Molecular Playground] (see also [[Molecular Playground|Molecular Playground in Proteopedia]]). Follow the links below to read nontechnical descriptions, in Proteopedia, of these molecules.&lt;br /&gt;
&lt;br /&gt;
UMass CBI Members, add your molecules to the list (which is alphabetical by CBI research mentor); follow the instructions below the list.&lt;br /&gt;
&lt;br /&gt;
Fall 2013: CBI Molecules are due 12/4/13 and should be added at the TOP of the list from your lab. Label it as &amp;quot;in progress&amp;quot; until you are finished, and then as &amp;quot;New 2013&amp;quot; or &amp;quot;Revised 2013&amp;quot;. For those editing an existing CBI Molecule, start from that entry so that it retains the full author list of all authors that contributed (or include credits to the original page and authors if it does not).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Molecules==&lt;br /&gt;
&#039;&#039;&#039;** Designates CBI Molecules Featured on [http://http://www.umass.edu/cbi/ CBI website]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
Bhatia Lab&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Alginate-Fall2011]]&#039;&#039;&#039;, Joe White, David Griffin&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Alginate-Fall2010]]&#039;&#039;&#039;, Joe White, David Griffin&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Poly(ethylene glycol)]]&#039;&#039;&#039;, Erika M. Saffer&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://chamberslab.com/wp/ Chambers Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Glutamate Receptor]]&#039;&#039;&#039;,  Amanda Hussey, Steve McCarron, Rosie Combs-Bachmann, Mariel Feliciano&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.chem.umass.edu/~chenlab/index.HTML Chen Lab]&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/OmpG]]&#039;&#039;&#039;, Christina Chisholm&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/ClyA]]&#039;&#039;&#039;, Bib Yang&lt;br /&gt;
&lt;br /&gt;
[http://openwetware.org/wiki/Chien Chien Lab]&lt;br /&gt;
&lt;br /&gt;
New Fall 2013! : **&#039;&#039;&#039;[[Molecular Playground/Homo-dimeric RcdA]]&#039;&#039;&#039;, Kamal K. Joshi &lt;br /&gt;
&lt;br /&gt;
: **&#039;&#039;&#039;[[Molecular Playground/Hexameric ClpX]]&#039;&#039;&#039;, Joanne Lau &lt;br /&gt;
:: Best CBI Molecule 2011&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/DNA replication initiator DnaA]]&#039;&#039;&#039;, Jing Liu&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Forbes Lab&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/CheR]]&#039;&#039;&#039;,  Miaomin Zhang&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/RBP]]&#039;&#039;&#039;,  Jan Panteli&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/TRAIL]]&#039;&#039;&#039;,  Charley Swofford&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.biochem.umass.edu/garman/index.html Garman Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Human Protective Protein Cathepsin A]]&#039;&#039;&#039;, Yadilette Rivera-Colon&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Human PPCA]]&#039;&#039;&#039;, Nilima Kolli&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/gieraschlab/ Gierasch Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[CRABP I ( Cellular Retinoic Acid Binding Protein )|Molecular Playground/CRABP I]]&#039;&#039;&#039;, Kristine Faye Pobre, Mylene Ferrolino,Mangai Periasamy&lt;br /&gt;
:: Best Overall CBI Molecule 2010&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/CRABP I (Cellular Retinoic Acid Binding Protein)]]&#039;&#039;&#039;, Gustavo Elberto Epalza Sanchez&lt;br /&gt;
(compare this to the previous version above to see what&#039;s new)&lt;br /&gt;
&lt;br /&gt;
: **&#039;&#039;&#039;[[Molecular_Playground/DHFR]]&#039;&#039;&#039;, Karan Hingorani &lt;br /&gt;
:: Best CBI Molecule 2012&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/jhardy/ Hardy Lab]&lt;br /&gt;
&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/Executioner Caspase-7]]&#039;&#039;&#039;, Derek MacPherson, Maureen E. Hill&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/[[Caspase-3 Regulatory Mechanisms]]&#039;&#039;&#039;, Scott Eron, Bay Serrano, Yunlong Zhao&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039; [[Molecular Playground/Caspase-6 and neurodegeneration]]&#039;&#039;&#039;, Kevin Buadlart Dagbay&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Caspase-7 Dynamics]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Caspase-9 Regulation]]&#039;&#039;&#039;, Kristen Huber&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Caspase-6 (new)]]&#039;&#039;&#039;, Elih Velazquez&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Influenza A M2 transmembrane domain]]&#039;&#039;&#039;, Samantha Nicholls&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Dengue Virus Protease]]&#039;&#039;&#039;, Muslum Yildiz&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hebert Lab&lt;br /&gt;
&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular_Playground/Hsp70-Hsp90]]&#039;&#039;&#039;,  Jill Graham&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular_Playground/ERDj5]]&#039;&#039;&#039;,  Lydia Lamriben&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Saposin C]]&#039;&#039;&#039;, Abla Tannous&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular_Playground/ERMan1]]&#039;&#039;&#039;,  Johan Sunryd&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.biochem.umass.edu/aheuck/aph.html Heuck Lab]&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2012!! &#039;&#039;&#039;[[Molecular_Playground/Pcr H]]&#039;&#039;&#039;,  Fabian Romano, Carolina Morell-Pérez&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/mholden/ Holden Lab]&lt;br /&gt;
&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/Protective Antigen]]&#039;&#039;&#039;,  Jing Huang&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.chem.umass.edu/people/kaltashovlab/ Kaltashov Lab]&lt;br /&gt;
&lt;br /&gt;
: New 2013! &#039;&#039;&#039;[http://proteopedia.org/wiki/index.php/Chengfeng_Ren Molecular Playground/Inteferon]&#039;&#039;&#039;, Chengfeng Ren&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2012!! &#039;&#039;&#039; [[Molecular Playground/Transferrin]]&#039;&#039;&#039;, Khaja Muneeruddin, Jake Pawlowski&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Velaglucerase]]&#039;&#039;&#039;, Adriana Kita&lt;br /&gt;
&lt;br /&gt;
: New Summer 2014!! &#039;&#039;&#039;[[Molecular Playground/Antithrombin-Heparin]]&#039;&#039;&#039;, Yunlong Zhao&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Knapp lab&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/FIH]]&#039;&#039;&#039;, Vanessa Chaplin, Cornelius Taabazuing, Breanne Holmes, John Hangasky&lt;br /&gt;
 &lt;br /&gt;
: Updated Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/Prolyl Hydroxylase Domain (PHD) Enzyme]]&#039;&#039;&#039;, Cristina Martin, Serap Pektas&lt;br /&gt;
:: Best CBI Molecule Proteopedia Page 2010&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/mmaroney/ Maroney Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Nickel Superoxide Dismutase]]&#039;&#039;&#039;, Carolyn Carr&lt;br /&gt;
: Updated Fall 2013!!  &#039;&#039;&#039;[[Molecular Playground/CsoR and RcnR]]&#039;&#039;&#039;, Heidi Hu, Carolyn Carr&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/HypA]]&#039;&#039;&#039;, Heidi Hu&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.chem.umass.edu/~cmartin/ Martin Lab]&lt;br /&gt;
&lt;br /&gt;
: **&#039;&#039;&#039;[[Molecular Playground/T7 RNAP Conformations]]&#039;&#039;&#039;, Luis E. Ramirez-Tapia &lt;br /&gt;
:: Best CBI Molecule 2011&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/T7 RNA Polymerase (7 mer int)]]&#039;&#039;&#039;, Ankit Vahia&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Human mtRNA pol]]&#039;&#039;&#039;, Ketan Mathavan &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.peytonlab.org/ Peyton Lab]&lt;br /&gt;
: New Fall 2013! &#039;&#039;&#039;[[Molecular Playground/MMP14]]&#039;&#039;&#039;, Lauren Jansen&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/C-Raf]]&#039;&#039;&#039;, Thuy Nguyen&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/FAK]]&#039;&#039;&#039;, Dannielle Ryman&lt;br /&gt;
&lt;br /&gt;
[http://roberts.openwetware.org/ Roberts Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Taxol]]&#039;&#039;&#039;,  Rohan Patil, Sarah Wilson&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Insulin]]&#039;&#039;&#039;, Whitney Stoppel&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.umass.edu/rotellogroup/ Rotello Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Reverse transcriptase|Molecular Playground/Reverse Transcriptase]]&#039;&#039;&#039;, Daniel Moyano-Marino&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Pancreatic Lipase]]&#039;&#039;&#039;,  Rui Tang&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular playground/Chymotrypsin]]&#039;&#039;&#039;,  Brad&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Targeting Peptide]]&#039;&#039;&#039;, David Solfiell&lt;br /&gt;
&lt;br /&gt;
[http://http://www.umass.edu/schiffman/  Schiffman Lab]&lt;br /&gt;
:New Fall 2013! &#039;&#039;&#039;[[Molecular Playground/Streptavidin]]&#039;&#039;&#039;, Katrina Rieger&lt;br /&gt;
&lt;br /&gt;
[https://elements.chem.umass.edu/schnarrlab/ Schnarr Lab] &lt;br /&gt;
&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/4&#039;-PHOSPHOPANTETHEINYL TRANSFERASE (Sfp)]]&#039;&#039;&#039;, Jon Amoroso, Gitanjeli Prasad, Lawrence Sheringham Borketey &lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[6-deoxyerythronolide_B_synthase_(DEBS)|Molecular Playground/6-Deoxyerythronolide B Synthase]]&#039;&#039;&#039;, Tsung-Yi Lin, Jon Amoroso, Lawrence Sheringham Borketey&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/ACP apo]]&#039;&#039;&#039;, Gitanjeli Prasad&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.biochem.umass.edu/faculty/danny-j-schnell Schnell Lab]&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/Tic40]]&#039;&#039;&#039;, Mine Canakci&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Tew Lab&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2013!!  &#039;&#039;&#039;[[Molecular Playground/HIV Tat]]&#039;&#039;&#039;, Brittany deRonde&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Thayumanavan Lab&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Interleukin-1 beta]]&#039;&#039;&#039;, Huan He&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Lysozyme ]]&#039;&#039;&#039;, Daniella Gonzalez&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Beta-galactosidase]]&#039;&#039;&#039;, Judy Ventura&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[User:Krishna Reddy Ragupathi|Molecular Playground/Carbonic Anhydrase]]&#039;&#039;&#039;, Krishna Reddy Raghupathi&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[User:Rami Rajasekhar Reddy|Molecular Playground/Avidin]]&#039;&#039;&#039;, Rami Rajasekar Reddy&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Biotin binding avidin]]&#039;&#039;&#039;, Diego Amado &lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[User:Jiaming Zhuang|Molecular Playground/MMP12]]&#039;&#039;&#039;, Jiaming Zhuang&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039; [[User:Jing Guo|Molecular Playground/Gluconase]]&#039;&#039;&#039;, Jing Guo&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Glutathione Reductase]]&#039;&#039;&#039;, Reuben Chacko&lt;br /&gt;
&lt;br /&gt;
Thayumanavan &amp;amp; Vachet Labs&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Trypsin]]&#039;&#039;&#039;, Gladys Murage&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/thompson/index.html Thompson] &amp;amp; [http://www.chem.umass.edu/~rmweis/weislab/ Weis] Labs&lt;br /&gt;
&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/Bacterial Chemotaxis Complex]]&#039;&#039;&#039;, Elizabeth R. Haglin, Maryam Kashefi&lt;br /&gt;
&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/CheA]]&#039;&#039;&#039;, Elizabeth R. Haglin&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Bacterial Chemotaxis Receptors]]&#039;&#039;&#039;, Lynmarie K. Thompson, Shiela M. Jones&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/cytoplasmic domain of a serine chemotaxis receptor]]&#039;&#039;&#039;,  Meili Yang&lt;br /&gt;
&lt;br /&gt;
: Updated 2013!! &#039;&#039;&#039;[[Molecular Playground/Cytoplasmic domain of chemoreceptor of Thermotoga maritima]]&#039;&#039;&#039;,  Xuni Li&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.chem.umass.edu/~vachet/index.html Vachet Lab]&lt;br /&gt;
&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/Human Serum Albumin]]&#039;&#039;&#039;, Mahalia Serrano&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular playground/beta 2 microglobulin]]&#039;&#039;&#039;,  Nick Borotto&lt;br /&gt;
:: Best CBI Molecule Jmol scenes 2010&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Myoglobin]]&#039;&#039;&#039;,  Yuping Zhou &lt;br /&gt;
&lt;br /&gt;
:&#039;&#039;&#039;[[Molecular Playground/ Copper-Zinc Superoxide Dismutase]]&#039;&#039;&#039;, Shaynah Browne&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Ubiquitin salt bridge discussion]]&#039;&#039;&#039;, Zhe Zhang&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Other Molecules of interest&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/PcrA Helicase]]&#039;&#039;&#039;, Luis E Ramirez-Tapia, [http://www.chem.umass.edu/~cmartin/ Martin Lab]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Other Laboratories&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/YKL-40]]&#039;&#039;&#039;, Ralph A. Francescone III, [http://www.bio.umass.edu/mcb/faculty/Shao.html Shao Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/BLG|Molecular Playground/β-lactoglobulin]]&#039;&#039;&#039;, Daniel Seeman, Dubin Lab&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/ADAM13]]&#039;&#039;&#039;, Genevieve Abbruzzese, Alfandari Lab&lt;br /&gt;
&lt;br /&gt;
==Instructions==&lt;br /&gt;
&lt;br /&gt;
&#039;&#039;&#039;The goal is for students to work collaboratively to create one excellent CBI Molecule for each CBI research group, to be featured on the CBI website.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
Fall 2013: Complete steps 1-2 by 10/18, and bring your computer to the CBI Molecule Workshop on Wed 10/23 in ISB 321. &lt;br /&gt;
&lt;br /&gt;
A successful CBI Molecule will be an interesting, nontechnical description of a molecule related to your group&#039;s research. It should not be super long, but instead have multiple green scenes. Green scenes should clearly show an interesting feature and should be attractive. Use the green scenes to help you make interesting points about the molecule (do not try to describe every feature of the molecule). It&#039;s great if you can end with a brief statement about how it relates to your group&#039;s research goals.&lt;br /&gt;
&lt;br /&gt;
1. If you don&#039;t already have one, request a Proteopedia account and log in. &lt;br /&gt;
&lt;br /&gt;
2. Read through the rest of the instructions and look at any existing CBI Molecules from your research group. Talk with other Chalk Talk students in your research group and think about how you can make a new or improved CBI Molecule related to your group&#039;s research. Develop ideas for the scenes you wish to show. You will work learn how to make scenes during the workshop. &lt;br /&gt;
&lt;br /&gt;
3. Get started working in Proteopedia by using the links at [[Help:Contents]]. Make yourself a sandbox page: Enter &amp;quot;User:Your Name/Sandbox 1&amp;quot; (omit quotes) in the search box, then follow instructions to edit this page. Practice entering text, inserting a structure window with scrolling text (green 4-square button on the right), and creating a green scene. You can look at other Proteopedia pages in edit mode to see how different effects (like colored text) are achieved (but this won&#039;t show you how the scene effects are made). &lt;br /&gt;
&lt;br /&gt;
4. For those editing an existing CBI Molecule, start from that entry so that it retains the full author list of all authors that contributed. You are encouraged to collaborate on the CBI Molecules, but everyone will need to do some editing of the molecule so that they each appear as authors on the final list. If you are the sole student from your group enrolled in Chalk Talk and have not previously made a CBI Molecule, try to convince another group member who has previously made a CBI Molecule (see  list above) to join us for the workshop so that you can work together.&lt;br /&gt;
&lt;br /&gt;
5. Your final pages should be called &amp;quot;Molecular Playground/your molecule&amp;quot; and should have links on this CBI Molecule page -- put the new ones first on the list from your research group. Label them &amp;quot;in progress&amp;quot; until you are finished, and then &amp;quot;new 2013&amp;quot; or &amp;quot;revised 2013&amp;quot;.&lt;br /&gt;
&lt;br /&gt;
==Links to HELP pages==&lt;br /&gt;
Overview at [[Help:Contents ]]&lt;br /&gt;
&lt;br /&gt;
See also [[Help:Getting_Started_in_Proteopedia]] &lt;br /&gt;
&lt;br /&gt;
Videos showing how to use Proteopedia:&lt;br /&gt;
[[Proteopedia:Video_Guide]]&lt;br /&gt;
(Sometimes slow -- if you pause the video and wait awhile it will download and then you can play it without interruptions)&lt;br /&gt;
&lt;br /&gt;
[[Proteopedia:DIY:Scenes|Proteopedia Scenes: Do It Yourself]]&lt;br /&gt;
gives succinct step by step instructions on how to create a molecular scene.&lt;br /&gt;
&lt;br /&gt;
A powerpoint-like set of slides that walks a user through the process of creating a new page and a new molecular scene/green link.&lt;br /&gt;
[http://www.proteopedia.org/wiki/images/1/1b/2009_07_13_Proteopedia_Workshop.pdf Proteopedia Workshop Slides]&lt;br /&gt;
&lt;br /&gt;
[[Proteopedia:Guidelines for Ethical Writing]].&lt;br /&gt;
Please pay attention to the section about images. There are links to examples of images re-used with explicit permission.&lt;br /&gt;
&lt;br /&gt;
For other help resources, click on [[Help:Contents|Help]] in the &#039;&#039;navigation&#039;&#039; box at the upper left of every page in Proteopedia.&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=CBI_Molecules&amp;diff=1926542</id>
		<title>CBI Molecules</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=CBI_Molecules&amp;diff=1926542"/>
		<updated>2014-05-12T14:00:21Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;These are molecules under study by members of the [http://www.umass.edu/cbi/ University of Massachusetts Amherst Chemistry-Biology Interface Program].&lt;br /&gt;
Many of the  molecules we study are featured at the [http://www.molecularplayground.org/ Molecular Playground] (see also [[Molecular Playground|Molecular Playground in Proteopedia]]). Follow the links below to read nontechnical descriptions, in Proteopedia, of these molecules.&lt;br /&gt;
&lt;br /&gt;
UMass CBI Members, add your molecules to the list (which is alphabetical by CBI research mentor); follow the instructions below the list.&lt;br /&gt;
&lt;br /&gt;
Fall 2013: CBI Molecules are due 12/4/13 and should be added at the TOP of the list from your lab. Label it as &amp;quot;in progress&amp;quot; until you are finished, and then as &amp;quot;New 2013&amp;quot; or &amp;quot;Revised 2013&amp;quot;. For those editing an existing CBI Molecule, start from that entry so that it retains the full author list of all authors that contributed (or include credits to the original page and authors if it does not).&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==Molecules==&lt;br /&gt;
&#039;&#039;&#039;** Designates CBI Molecules Featured on [http://http://www.umass.edu/cbi/ CBI website]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
Bhatia Lab&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Alginate-Fall2011]]&#039;&#039;&#039;, Joe White, David Griffin&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Alginate-Fall2010]]&#039;&#039;&#039;, Joe White, David Griffin&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Poly(ethylene glycol)]]&#039;&#039;&#039;, Erika M. Saffer&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://chamberslab.com/wp/ Chambers Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Glutamate Receptor]]&#039;&#039;&#039;,  Amanda Hussey, Steve McCarron, Rosie Combs-Bachmann, Mariel Feliciano&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.chem.umass.edu/~chenlab/index.HTML Chen Lab]&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/OmpG]]&#039;&#039;&#039;, Christina Chisholm&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/ClyA]]&#039;&#039;&#039;, Bib Yang&lt;br /&gt;
&lt;br /&gt;
[http://openwetware.org/wiki/Chien Chien Lab]&lt;br /&gt;
&lt;br /&gt;
New Fall 2013! : **&#039;&#039;&#039;[[Molecular Playground/Homo-dimeric RcdA]]&#039;&#039;&#039;, Kamal K. Joshi &lt;br /&gt;
&lt;br /&gt;
: **&#039;&#039;&#039;[[Molecular Playground/Hexameric ClpX]]&#039;&#039;&#039;, Joanne Lau &lt;br /&gt;
:: Best CBI Molecule 2011&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/DNA replication initiator DnaA]]&#039;&#039;&#039;, Jing Liu&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Forbes Lab&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/CheR]]&#039;&#039;&#039;,  Miaomin Zhang&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/RBP]]&#039;&#039;&#039;,  Jan Panteli&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/TRAIL]]&#039;&#039;&#039;,  Charley Swofford&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.biochem.umass.edu/garman/index.html Garman Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Human Protective Protein Cathepsin A]]&#039;&#039;&#039;, Yadilette Rivera-Colon&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Human PPCA]]&#039;&#039;&#039;, Nilima Kolli&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/gieraschlab/ Gierasch Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[CRABP I ( Cellular Retinoic Acid Binding Protein )|Molecular Playground/CRABP I]]&#039;&#039;&#039;, Kristine Faye Pobre, Mylene Ferrolino,Mangai Periasamy&lt;br /&gt;
:: Best Overall CBI Molecule 2010&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/CRABP I (Cellular Retinoic Acid Binding Protein)]]&#039;&#039;&#039;, Gustavo Elberto Epalza Sanchez&lt;br /&gt;
(compare this to the previous version above to see what&#039;s new)&lt;br /&gt;
&lt;br /&gt;
: **&#039;&#039;&#039;[[Molecular_Playground/DHFR]]&#039;&#039;&#039;, Karan Hingorani &lt;br /&gt;
:: Best CBI Molecule 2012&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/jhardy/ Hardy Lab]&lt;br /&gt;
&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/Executioner Caspase-7]]&#039;&#039;&#039;, Derek MacPherson, Maureen E. Hill&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/[[Caspase-3 Regulatory Mechanisms]]&#039;&#039;&#039;, Scott Eron, Bay Serrano, Yunlong Zhao&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039; [[Molecular Playground/Caspase-6 and neurodegeneration]]&#039;&#039;&#039;, Kevin Buadlart Dagbay&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Caspase-7 Dynamics]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Caspase-9 Regulation]]&#039;&#039;&#039;, Kristen Huber&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Caspase-6 (new)]]&#039;&#039;&#039;, Elih Velazquez&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Influenza A M2 transmembrane domain]]&#039;&#039;&#039;, Samantha Nicholls&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Dengue Virus Protease]]&#039;&#039;&#039;, Muslum Yildiz&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Hebert Lab&lt;br /&gt;
&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular_Playground/Hsp70-Hsp90]]&#039;&#039;&#039;,  Jill Graham&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular_Playground/ERDj5]]&#039;&#039;&#039;,  Lydia Lamriben&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Saposin C]]&#039;&#039;&#039;, Abla Tannous&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular_Playground/ERMan1]]&#039;&#039;&#039;,  Johan Sunryd&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.biochem.umass.edu/aheuck/aph.html Heuck Lab]&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2012!! &#039;&#039;&#039;[[Molecular_Playground/Pcr H]]&#039;&#039;&#039;,  Fabian Romano, Carolina Morell-Pérez&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/mholden/ Holden Lab]&lt;br /&gt;
&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/Protective Antigen]]&#039;&#039;&#039;,  Jing Huang&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.chem.umass.edu/people/kaltashovlab/ Kaltashov Lab]&lt;br /&gt;
&lt;br /&gt;
New 2013! &#039;&#039;&#039;[http://proteopedia.org/wiki/index.php/Chengfeng_Ren Molecular Playground/Inteferon]&#039;&#039;&#039;, Chengfeng Ren&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2012!! &#039;&#039;&#039; [[Molecular Playground/Transferrin]]&#039;&#039;&#039;, Khaja Muneeruddin, Jake Pawlowski&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Velaglucerase]]&#039;&#039;&#039;, Adriana Kita&lt;br /&gt;
&lt;br /&gt;
: New Summer 2014!! &#039;&#039;&#039;[[Molecular Playground/Antithrombin-Heparin]]&#039;&#039;&#039;, Yunlong Zhao&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Knapp lab&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/FIH]]&#039;&#039;&#039;, Vanessa Chaplin, Cornelius Taabazuing, Breanne Holmes, John Hangasky&lt;br /&gt;
 &lt;br /&gt;
: Updated Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/Prolyl Hydroxylase Domain (PHD) Enzyme]]&#039;&#039;&#039;, Cristina Martin, Serap Pektas&lt;br /&gt;
:: Best CBI Molecule Proteopedia Page 2010&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/mmaroney/ Maroney Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Nickel Superoxide Dismutase]]&#039;&#039;&#039;, Carolyn Carr&lt;br /&gt;
: Updated Fall 2013!!  &#039;&#039;&#039;[[Molecular Playground/CsoR and RcnR]]&#039;&#039;&#039;, Heidi Hu, Carolyn Carr&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/HypA]]&#039;&#039;&#039;, Heidi Hu&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.chem.umass.edu/~cmartin/ Martin Lab]&lt;br /&gt;
&lt;br /&gt;
: **&#039;&#039;&#039;[[Molecular Playground/T7 RNAP Conformations]]&#039;&#039;&#039;, Luis E. Ramirez-Tapia &lt;br /&gt;
:: Best CBI Molecule 2011&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/T7 RNA Polymerase (7 mer int)]]&#039;&#039;&#039;, Ankit Vahia&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Human mtRNA pol]]&#039;&#039;&#039;, Ketan Mathavan &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.peytonlab.org/ Peyton Lab]&lt;br /&gt;
: New Fall 2013! &#039;&#039;&#039;[[Molecular Playground/MMP14]]&#039;&#039;&#039;, Lauren Jansen&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/C-Raf]]&#039;&#039;&#039;, Thuy Nguyen&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/FAK]]&#039;&#039;&#039;, Dannielle Ryman&lt;br /&gt;
&lt;br /&gt;
[http://roberts.openwetware.org/ Roberts Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Taxol]]&#039;&#039;&#039;,  Rohan Patil, Sarah Wilson&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Insulin]]&#039;&#039;&#039;, Whitney Stoppel&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.umass.edu/rotellogroup/ Rotello Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Reverse transcriptase|Molecular Playground/Reverse Transcriptase]]&#039;&#039;&#039;, Daniel Moyano-Marino&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Pancreatic Lipase]]&#039;&#039;&#039;,  Rui Tang&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular playground/Chymotrypsin]]&#039;&#039;&#039;,  Brad&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Targeting Peptide]]&#039;&#039;&#039;, David Solfiell&lt;br /&gt;
&lt;br /&gt;
[http://http://www.umass.edu/schiffman/  Schiffman Lab]&lt;br /&gt;
:New Fall 2013! &#039;&#039;&#039;[[Molecular Playground/Streptavidin]]&#039;&#039;&#039;, Katrina Rieger&lt;br /&gt;
&lt;br /&gt;
[https://elements.chem.umass.edu/schnarrlab/ Schnarr Lab] &lt;br /&gt;
&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/4&#039;-PHOSPHOPANTETHEINYL TRANSFERASE (Sfp)]]&#039;&#039;&#039;, Jon Amoroso, Gitanjeli Prasad, Lawrence Sheringham Borketey &lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[6-deoxyerythronolide_B_synthase_(DEBS)|Molecular Playground/6-Deoxyerythronolide B Synthase]]&#039;&#039;&#039;, Tsung-Yi Lin, Jon Amoroso, Lawrence Sheringham Borketey&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/ACP apo]]&#039;&#039;&#039;, Gitanjeli Prasad&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.biochem.umass.edu/faculty/danny-j-schnell Schnell Lab]&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/Tic40]]&#039;&#039;&#039;, Mine Canakci&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Tew Lab&lt;br /&gt;
&lt;br /&gt;
: Updated Fall 2013!!  &#039;&#039;&#039;[[Molecular Playground/HIV Tat]]&#039;&#039;&#039;, Brittany deRonde&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Thayumanavan Lab&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Interleukin-1 beta]]&#039;&#039;&#039;, Huan He&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Lysozyme ]]&#039;&#039;&#039;, Daniella Gonzalez&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Beta-galactosidase]]&#039;&#039;&#039;, Judy Ventura&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[User:Krishna Reddy Ragupathi|Molecular Playground/Carbonic Anhydrase]]&#039;&#039;&#039;, Krishna Reddy Raghupathi&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[User:Rami Rajasekhar Reddy|Molecular Playground/Avidin]]&#039;&#039;&#039;, Rami Rajasekar Reddy&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Biotin binding avidin]]&#039;&#039;&#039;, Diego Amado &lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[User:Jiaming Zhuang|Molecular Playground/MMP12]]&#039;&#039;&#039;, Jiaming Zhuang&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039; [[User:Jing Guo|Molecular Playground/Gluconase]]&#039;&#039;&#039;, Jing Guo&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Glutathione Reductase]]&#039;&#039;&#039;, Reuben Chacko&lt;br /&gt;
&lt;br /&gt;
Thayumanavan &amp;amp; Vachet Labs&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Trypsin]]&#039;&#039;&#039;, Gladys Murage&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://people.chem.umass.edu/thompson/index.html Thompson] &amp;amp; [http://www.chem.umass.edu/~rmweis/weislab/ Weis] Labs&lt;br /&gt;
&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/Bacterial Chemotaxis Complex]]&#039;&#039;&#039;, Elizabeth R. Haglin, Maryam Kashefi&lt;br /&gt;
&lt;br /&gt;
: New Fall 2012!! &#039;&#039;&#039;[[Molecular Playground/CheA]]&#039;&#039;&#039;, Elizabeth R. Haglin&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Bacterial Chemotaxis Receptors]]&#039;&#039;&#039;, Lynmarie K. Thompson, Shiela M. Jones&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/cytoplasmic domain of a serine chemotaxis receptor]]&#039;&#039;&#039;,  Meili Yang&lt;br /&gt;
&lt;br /&gt;
: Updated 2013!! &#039;&#039;&#039;[[Molecular Playground/Cytoplasmic domain of chemoreceptor of Thermotoga maritima]]&#039;&#039;&#039;,  Xuni Li&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
[http://www.chem.umass.edu/~vachet/index.html Vachet Lab]&lt;br /&gt;
&lt;br /&gt;
: New Fall 2013!! &#039;&#039;&#039;[[Molecular Playground/Human Serum Albumin]]&#039;&#039;&#039;, Mahalia Serrano&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular playground/beta 2 microglobulin]]&#039;&#039;&#039;,  Nick Borotto&lt;br /&gt;
:: Best CBI Molecule Jmol scenes 2010&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Myoglobin]]&#039;&#039;&#039;,  Yuping Zhou &lt;br /&gt;
&lt;br /&gt;
:&#039;&#039;&#039;[[Molecular Playground/ Copper-Zinc Superoxide Dismutase]]&#039;&#039;&#039;, Shaynah Browne&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/Ubiquitin salt bridge discussion]]&#039;&#039;&#039;, Zhe Zhang&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Other Molecules of interest&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/PcrA Helicase]]&#039;&#039;&#039;, Luis E Ramirez-Tapia, [http://www.chem.umass.edu/~cmartin/ Martin Lab]&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Other Laboratories&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/YKL-40]]&#039;&#039;&#039;, Ralph A. Francescone III, [http://www.bio.umass.edu/mcb/faculty/Shao.html Shao Lab]&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/BLG|Molecular Playground/β-lactoglobulin]]&#039;&#039;&#039;, Daniel Seeman, Dubin Lab&lt;br /&gt;
&lt;br /&gt;
: &#039;&#039;&#039;[[Molecular Playground/ADAM13]]&#039;&#039;&#039;, Genevieve Abbruzzese, Alfandari Lab&lt;br /&gt;
&lt;br /&gt;
==Instructions==&lt;br /&gt;
&lt;br /&gt;
&#039;&#039;&#039;The goal is for students to work collaboratively to create one excellent CBI Molecule for each CBI research group, to be featured on the CBI website.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
Fall 2013: Complete steps 1-2 by 10/18, and bring your computer to the CBI Molecule Workshop on Wed 10/23 in ISB 321. &lt;br /&gt;
&lt;br /&gt;
A successful CBI Molecule will be an interesting, nontechnical description of a molecule related to your group&#039;s research. It should not be super long, but instead have multiple green scenes. Green scenes should clearly show an interesting feature and should be attractive. Use the green scenes to help you make interesting points about the molecule (do not try to describe every feature of the molecule). It&#039;s great if you can end with a brief statement about how it relates to your group&#039;s research goals.&lt;br /&gt;
&lt;br /&gt;
1. If you don&#039;t already have one, request a Proteopedia account and log in. &lt;br /&gt;
&lt;br /&gt;
2. Read through the rest of the instructions and look at any existing CBI Molecules from your research group. Talk with other Chalk Talk students in your research group and think about how you can make a new or improved CBI Molecule related to your group&#039;s research. Develop ideas for the scenes you wish to show. You will work learn how to make scenes during the workshop. &lt;br /&gt;
&lt;br /&gt;
3. Get started working in Proteopedia by using the links at [[Help:Contents]]. Make yourself a sandbox page: Enter &amp;quot;User:Your Name/Sandbox 1&amp;quot; (omit quotes) in the search box, then follow instructions to edit this page. Practice entering text, inserting a structure window with scrolling text (green 4-square button on the right), and creating a green scene. You can look at other Proteopedia pages in edit mode to see how different effects (like colored text) are achieved (but this won&#039;t show you how the scene effects are made). &lt;br /&gt;
&lt;br /&gt;
4. For those editing an existing CBI Molecule, start from that entry so that it retains the full author list of all authors that contributed. You are encouraged to collaborate on the CBI Molecules, but everyone will need to do some editing of the molecule so that they each appear as authors on the final list. If you are the sole student from your group enrolled in Chalk Talk and have not previously made a CBI Molecule, try to convince another group member who has previously made a CBI Molecule (see  list above) to join us for the workshop so that you can work together.&lt;br /&gt;
&lt;br /&gt;
5. Your final pages should be called &amp;quot;Molecular Playground/your molecule&amp;quot; and should have links on this CBI Molecule page -- put the new ones first on the list from your research group. Label them &amp;quot;in progress&amp;quot; until you are finished, and then &amp;quot;new 2013&amp;quot; or &amp;quot;revised 2013&amp;quot;.&lt;br /&gt;
&lt;br /&gt;
==Links to HELP pages==&lt;br /&gt;
Overview at [[Help:Contents ]]&lt;br /&gt;
&lt;br /&gt;
See also [[Help:Getting_Started_in_Proteopedia]] &lt;br /&gt;
&lt;br /&gt;
Videos showing how to use Proteopedia:&lt;br /&gt;
[[Proteopedia:Video_Guide]]&lt;br /&gt;
(Sometimes slow -- if you pause the video and wait awhile it will download and then you can play it without interruptions)&lt;br /&gt;
&lt;br /&gt;
[[Proteopedia:DIY:Scenes|Proteopedia Scenes: Do It Yourself]]&lt;br /&gt;
gives succinct step by step instructions on how to create a molecular scene.&lt;br /&gt;
&lt;br /&gt;
A powerpoint-like set of slides that walks a user through the process of creating a new page and a new molecular scene/green link.&lt;br /&gt;
[http://www.proteopedia.org/wiki/images/1/1b/2009_07_13_Proteopedia_Workshop.pdf Proteopedia Workshop Slides]&lt;br /&gt;
&lt;br /&gt;
[[Proteopedia:Guidelines for Ethical Writing]].&lt;br /&gt;
Please pay attention to the section about images. There are links to examples of images re-used with explicit permission.&lt;br /&gt;
&lt;br /&gt;
For other help resources, click on [[Help:Contents|Help]] in the &#039;&#039;navigation&#039;&#039; box at the upper left of every page in Proteopedia.&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Molecular_Playground/Antithrombin-Heparin&amp;diff=1926443</id>
		<title>Molecular Playground/Antithrombin-Heparin</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Molecular_Playground/Antithrombin-Heparin&amp;diff=1926443"/>
		<updated>2014-05-11T14:00:49Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: New page: == Anticoagulant effects of heparin == &amp;lt;StructureSection load=&amp;#039;1azx&amp;#039; size=&amp;#039;340&amp;#039; side=&amp;#039;right&amp;#039; caption=&amp;#039;Dimer of Pentasaccharides-bound Antithrombin&amp;#039; scene=&amp;#039;&amp;#039;&amp;gt; == Introduction == Heparin is ...&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulant effects of heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Dimer of Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins.&amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts.&amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents.&amp;lt;ref&amp;gt;PMID:9405673&amp;lt;/ref&amp;gt; Pentasaccharide binds to the &amp;lt;scene name=&#039;58/584311/Binding_helices/3&#039;&amp;gt;helical region&amp;lt;/scene&amp;gt; distal to the inhibitory loop, which is pushed outward to make the contact with protease (eg. thrombin or factor Xa) easier. Although the plenty of charge on heparin strongly suggests that majority of interaction between antithrombin and heparin in solution is the electrostatic force, the distance between those two appears to be very close when heparin approaches AT-III during crystallization. This short distance implies that multiple hydrogen bond could be formed on the interface with helical region, supported by the crystal structure. The residues from the helical region of heparin-binding domain that contribute to &amp;lt;scene name=&#039;58/584311/Hydrogen_bond/5&#039;&amp;gt;H-bonding&amp;lt;/scene&amp;gt; interaction include Arg129, Lys125, Lys 11, Lys114, Arg13, Asn45, Arg46, Arg47 and Glu113 (shown in lime). Most of those residues are positively charged and can potentially attract the negative charges on sulfate groups of heparin to initialize those sidechains orientation. Interestingly, if comparing with the non-heparin structure of AT-III, some conformation differences are observed in pentasaccharide-binding structure. For example, the attachment of pentasaccharide to the helical region induces a unique &amp;lt;scene name=&#039;58/584311/Induced_helix_extension/1&#039;&amp;gt;helix extension&amp;lt;/scene&amp;gt;. Three positively charged sidechains Lys133, Lys136 and Arg136 on the extended helix are most possible to be affected by the pentasaccharide-bindng. Those secondary structures rearrangement may offer some torsion forces and finally lead the inhibitory loop to shift allosterically. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926442</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926442"/>
		<updated>2014-05-11T13:56:41Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulant effects of heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Dimer of Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins.&amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts.&amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents.&amp;lt;ref&amp;gt;PMID:9405673&amp;lt;/ref&amp;gt; Pentasaccharide binds to the &amp;lt;scene name=&#039;58/584311/Binding_helices/3&#039;&amp;gt;helical region&amp;lt;/scene&amp;gt; distal to the inhibitory loop, which is pushed outward to make the contact with protease (eg. thrombin or factor Xa) easier. Although the plenty of charge on heparin strongly suggests that majority of interaction between antithrombin and heparin in solution is the electrostatic force, the distance between those two appears to be very close when heparin approaches AT-III during crystallization. This short distance implies that multiple hydrogen bond could be formed on the interface with helical region, supported by the crystal structure. The residues from the helical region of heparin-binding domain that contribute to &amp;lt;scene name=&#039;58/584311/Hydrogen_bond/5&#039;&amp;gt;H-bonding&amp;lt;/scene&amp;gt; interaction include Arg129, Lys125, Lys 11, Lys114, Arg13, Asn45, Arg46, Arg47 and Glu113 (shown in lime). Most of those residues are positively charged and can potentially attract the negative charges on sulfate groups of heparin to initialize those sidechains orientation. Interestingly, if comparing with the non-heparin structure of AT-III, some conformation differences are observed in pentasaccharide-binding structure. For example, the attachment of pentasaccharide to the helical region induces a unique &amp;lt;scene name=&#039;58/584311/Induced_helix_extension/1&#039;&amp;gt;helix extension&amp;lt;/scene&amp;gt;. Three positively charged sidechains Lys133, Lys136 and Arg136 on the extended helix are most possible to be affected by the pentasaccharide-bindng. Those secondary structures rearrangement may offer some torsion forces and finally lead the inhibitory loop to shift allosterically. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926441</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926441"/>
		<updated>2014-05-11T13:53:51Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulant effects of heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins.&amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts.&amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents.&amp;lt;ref&amp;gt;PMID:9405673&amp;lt;/ref&amp;gt; Pentasaccharide binds to the &amp;lt;scene name=&#039;58/584311/Binding_helices/3&#039;&amp;gt;helical region&amp;lt;/scene&amp;gt; distal to the inhibitory loop, which is pushed outward to make the contact with protease (eg. thrombin or factor Xa) easier. Although the plenty of charge on heparin strongly suggests that majority of interaction between antithrombin and heparin in solution is the electrostatic force, the distance between those two appears to be very close when heparin approaches AT-III during crystallization. This short distance implies that multiple hydrogen bond could be formed on the interface with helical region, supported by the crystal structure. The residues from the helical region of heparin-binding domain that contribute to &amp;lt;scene name=&#039;58/584311/Hydrogen_bond/5&#039;&amp;gt;H-bonding&amp;lt;/scene&amp;gt; interaction include Arg129, Lys125, Lys 11, Lys114, Arg13, Asn45, Arg46, Arg47 and Glu113 (shown in lime). Most of those residues are positively charged and can potentially attract the negative charges on sulfate groups of heparin to initialize those sidechains orientation. Interestingly, if comparing with the non-heparin structure of AT-III, some conformation differences are observed in pentasaccharide-binding structure. For example, the attachment of pentasaccharide to the helical region induces a unique &amp;lt;scene name=&#039;58/584311/Induced_helix_extension/1&#039;&amp;gt;helix extension&amp;lt;/scene&amp;gt;. Three positively charged sidechains Lys133, Lys136 and Arg136 on the extended helix are most possible to be affected by the pentasaccharide-bindng. Those secondary structures rearrangement may offer some torsion forces and finally lead the inhibitory loop to shift allosterically. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926440</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926440"/>
		<updated>2014-05-11T13:48:39Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents. Pentasaccharide binds to the &amp;lt;scene name=&#039;58/584311/Binding_helices/3&#039;&amp;gt;helical region&amp;lt;/scene&amp;gt; distal to the inhibitory loop, which is pushed outward to make the contact with protease (eg. thrombin or factor Xa) easier. Although the plenty of charge on heparin strongly suggests that majority of interaction between antithrombin and heparin in solution is the electrostatic force, the distance between those two appears to be very close when heparin approaches AT-III during crystallization. This short distance implies that multiple hydrogen bond could be formed on the interface with helical region, supported by the crystal structure. The residues from the helical region of heparin-binding domain that contribute to &amp;lt;scene name=&#039;58/584311/Hydrogen_bond/5&#039;&amp;gt;H-bonding&amp;lt;/scene&amp;gt; interaction include Arg129, Lys125, Lys 11, Lys114, Arg13, Asn45, Arg46, Arg47 and Glu113 (shown in lime). Most of those residues are positively charged and can potentially attract the negative charges on sulfate groups of heparin to initialize those sidechains orientation. Interestingly, if comparing with the non-heparin structure of AT-III, some conformation differences are observed in pentasaccharide-binding structure. For example, the attachment of pentasaccharide to the helical region induces a unique &amp;lt;scene name=&#039;58/584311/Induced_helix_extension/1&#039;&amp;gt;helix extension&amp;lt;/scene&amp;gt;. Three positively charged sidechains Lys133, Lys136 and Arg136 on the extended helix are most possible to be affected by the pentasaccharide-bindng. Those secondary structures rearrangement may offer some torsion forces and finally lead the inhibitory loop to shift allosterically. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926439</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926439"/>
		<updated>2014-05-11T13:38:01Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents. Pentasaccharide binds to the &amp;lt;scene name=&#039;58/584311/Binding_helices/3&#039;&amp;gt;helical region&amp;lt;/scene&amp;gt; distal to the inhibitory loop, which is pushed outward to make the contact with protease (eg. thrombin or factor Xa) easier. Although the plenty of charge on heparin strongly suggests that majority of interaction between antithrombin and heparin in solution is the electrostatic force, the distance between those two appears to be very close when heparin approaches AT-III during crystallization. This short distance implies that multiple hydrogen bond could be formed on the interface with helical region, supported by the &amp;lt;scene name=&#039;58/584311/Hydrogen_bond/2&#039;&amp;gt;crystal structure&amp;lt;/scene&amp;gt;. The residues from the helical region of heparin-binding domain that contribute to H-bonding interaction include Arg129, Lys125, Lys 11, Lys114, Arg13, Asn45, Arg46, Arg47 and Glu113 (shown in lime). Most of those residues are positively charged and can potentially attract the negative charges on sulfate groups of heparin to initialize those sidechains orientation. Interestingly, if comparing with the non-heparin structure of AT-III, some conformation differences are observed in pentasaccharide-binding structure. For example, the attachment of pentasaccharide to the helical region induces a unique helix extension (shown in blue). Three positively charged sidechains Lys133, Lys136 and Arg136 on the extended helix are most possible to be affected by the pentasaccharide-bindng. Those secondary structures rearrangement may offer some torsion forces and finally lead the inhibitory loop to shift allosterically. &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926433</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926433"/>
		<updated>2014-05-11T11:53:16Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents. Pentasaccharide binds to the &amp;lt;scene name=&#039;58/584311/Binding_helices/3&#039;&amp;gt;helical region&amp;lt;/scene&amp;gt; distal to the inhibitory loop.&lt;br /&gt;
&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926432</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926432"/>
		<updated>2014-05-11T11:44:43Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents. Pentasaccharide binds to the &amp;lt;scene name=&#039;58/584311/Binding_helices/2&#039;&amp;gt;helix region&amp;lt;/scene&amp;gt; distal to the inhibitory loop.&lt;br /&gt;
&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926431</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926431"/>
		<updated>2014-05-11T11:36:59Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents. Pentasaccharide binds to the &amp;lt;scene name=&#039;58/584311/Binding_helices/1&#039;&amp;gt;helix region&amp;lt;/scene&amp;gt; distal to the inhibitory loop.&lt;br /&gt;
&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926430</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926430"/>
		<updated>2014-05-11T11:13:03Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents. Pentasaccharide binds to the helix region &amp;lt;scene name=&#039;58/584311/Overall_suface/1&#039;&amp;gt;distal&amp;lt;/scene&amp;gt; to the inhibitory loop.&lt;br /&gt;
&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926429</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926429"/>
		<updated>2014-05-11T11:11:49Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents. &amp;lt;scene name=&#039;58/584311/Overall_suface/1&#039;&amp;gt;TextToBeDisplayed&amp;lt;/scene&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=File:Inhibiory_AT-III_monomer.pdb&amp;diff=1926424</id>
		<title>File:Inhibiory AT-III monomer.pdb</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=File:Inhibiory_AT-III_monomer.pdb&amp;diff=1926424"/>
		<updated>2014-05-11T05:10:14Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926423</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926423"/>
		<updated>2014-05-11T04:55:42Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anti-coagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The allosteric mechanism of heparin-based anticoagulant activation ==&lt;br /&gt;
&lt;br /&gt;
A model of anticoagulant activation of antithrombin by heparin was described as an allosteric mechanism. In another word, heparin chain binds to antithrombin and stabilizes the inhibitory conformation (the inhibitory loop is outward) or alters the antithrombin conformation to facilitate the antithrombin-protease interaction. Early published crystal structure of pentasaccharide-bond antithrombin provided many details of the interaction and validated this hypothesis to some extents. &lt;br /&gt;
&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926422</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926422"/>
		<updated>2014-05-11T04:41:29Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anticoagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This reversible conformation change effectively switch antithrombin between on- and off-state.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1 The mechanism of latent antithrombin highlighted by a remarkable conformational rearrangement of the inhibitory loop.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
A model of heparin enhancement of antithrombin-protease interaction was based on an allosteric regulation.Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926421</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926421"/>
		<updated>2014-05-11T04:37:18Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anticoagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin, illustrated in fugure 1.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&#039;&#039;&#039;Figure 1&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926420</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926420"/>
		<updated>2014-05-11T04:36:54Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anticoagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop (shown in blue color in figure 1) to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin, illustrated in fugure 1.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]Figure 1&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926419</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926419"/>
		<updated>2014-05-11T04:17:02Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
== Introduction ==&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anticoagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin. The figure below shows the process of the activation of antithrombin.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926418</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1926418"/>
		<updated>2014-05-11T04:16:04Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Anticoagulation effects of heparin and the interaction with antithrombin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is a type of glycosaminoglycan chain that is secreted by human mast cell. Heparin exists in many isoforms and is often sulfated at specific sites. Because of the heterogeneity in structure and distribution of negative charge within those sulfate groups, heparin can bind multiple types of proteins and participate in many different biological processes, such as anticoagulation. Therefore polysaccharides, the low molecular weight products that are originated from digested heparin was often used in the therapy of many diseases such as atrial fibrillation and thrombosis.&lt;br /&gt;
&lt;br /&gt;
Heparin is usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that heparin exists in the form of “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin. The figure below shows the process of the activation of antithrombin.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923572</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923572"/>
		<updated>2014-05-06T21:08:50Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin. The figure below shows the process of the activation of antithrombin.&lt;br /&gt;
&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923571</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923571"/>
		<updated>2014-05-06T21:08:23Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin. The figure below shows the process of the activation of antithrombin.&lt;br /&gt;
[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923570</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923570"/>
		<updated>2014-05-06T21:08:11Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin. The figure below shows the process of the activation of antithrombin.[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923569</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923569"/>
		<updated>2014-05-06T21:07:57Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 (shown as the sphere model in figure 1) plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin. The figure below shows the process of the activation of antithrombin.[[Image:Activation_of_AT-III.png]Figure 1]&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923568</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923568"/>
		<updated>2014-05-06T21:03:59Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 plays a critical role in the inhibitory binding (Figure 1). However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin.[[Image:Activation_of_AT-III.png]]&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=File:Activation_of_AT-III.png&amp;diff=1923567</id>
		<title>File:Activation of AT-III.png</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=File:Activation_of_AT-III.png&amp;diff=1923567"/>
		<updated>2014-05-06T21:02:41Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Licensing ==&lt;br /&gt;
{{PD-self}}&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923566</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923566"/>
		<updated>2014-05-06T20:59:23Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 plays a critical role in the inhibitory binding (Figure 1). However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin.&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923565</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923565"/>
		<updated>2014-05-06T20:49:09Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 plays a critical role in the inhibitory binding (Figure 1). However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin.[[Image:Example.jpg]]&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923564</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923564"/>
		<updated>2014-05-06T20:15:14Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Antithrombin is a natural inhibitor of many serine proteases and it contains an exposed inhibitory loop to intrude the catalytic site of proteases. The peptide bond between R393-S394 plays a critical role in the inhibitory binding. However, the exposure of the inhibitory loop requires a conformational change during activation. In the latent state of antithrombin, this loop is fully buried in the four-strands beta sheet to form a new five-strands beta sheet. This remarkable conformational change of inhibitory loop highlights the activation mechanism of latent antithrombin.&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923563</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923563"/>
		<updated>2014-05-06T20:14:45Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Structure features and activation of latent antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923562</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923562"/>
		<updated>2014-05-06T20:13:31Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Pentasaccharides-bound Antithrombin&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923561</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923561"/>
		<updated>2014-05-06T20:11:36Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1azx&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923560</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923560"/>
		<updated>2014-05-06T14:56:57Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Activation of antithrombin by heparin ==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923559</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923559"/>
		<updated>2014-05-06T14:54:04Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins. &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt; Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts. &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923558</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923558"/>
		<updated>2014-05-06T14:52:33Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins &amp;lt;ref&amp;gt;PMID:6721831&amp;lt;/ref&amp;gt;. Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923557</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923557"/>
		<updated>2014-05-06T14:49:56Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins &amp;lt;ref&amp;gt;PMID:PMC1153400&amp;lt;/ref&amp;gt;. Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923556</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923556"/>
		<updated>2014-05-06T14:49:36Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins &amp;lt;ref&amp;gt;PMC1153400&amp;lt;/ref&amp;gt;. Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923555</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923555"/>
		<updated>2014-05-06T14:44:42Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins &amp;lt;ref&amp;gt;PMID:1153400&amp;lt;/ref&amp;gt;. Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923554</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923554"/>
		<updated>2014-05-06T14:44:18Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins &amp;lt;ref&amp;gt;PMCID:1153400&amp;lt;/ref&amp;gt;. Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923553</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923553"/>
		<updated>2014-05-06T14:43:46Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Heparin is often identified as a proteoglycan, in which heparin or heparin sulfate associates with other proteins in a strong intrinsic affinity. It has also been found that HS chains are usually localized on the surface of cells and the complex with matrix proteins. This interesting discovery suggests that HS usually exists as an “immobile phase” attaching antithrombin and activates its function as an anticoagulant factor in the circulation system. In an anticoagulant process, antithrombin needs to bind to some coagulant proteases such as Factor Xa or thrombin and “neutralizes” their activity. There are several hypotheses to explain how the heparin chains activate this process. A simple model is that a long heparin chain could be a scaffold to improve the possibility of antithrombin contacting with other proteins &amp;lt;ref&amp;gt;PMCID: PMC1153400&amp;lt;/ref&amp;gt;. Another direct model is that specific sulfate-containing heparin fragments (oligosaccharides) can allosterically enhance the binding affinity between antithrombin and thrombin or Factor Xa. We are going to describe the structural basis of the second model in the rest of contexts &amp;lt;ref&amp;gt;PMID:1618758&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923546</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923546"/>
		<updated>2014-05-05T17:54:55Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Antithrombin and thrombin interactions play an important role in multiple functions. Interestingly, an heparin or polysaccharides can regulate the function of antithrombin to different signaling. &amp;lt;ref&amp;gt;DOI 10.1021/bi034524y&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Heparin Binding site on antithrombin ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be a antithrombin specific site for binding heparin&lt;br /&gt;
Green scene 2 will be the complex with heparin&lt;br /&gt;
&lt;br /&gt;
== The mechanism of heparin regulating antithrombin thrombin interaction ==&lt;br /&gt;
&lt;br /&gt;
Green scene 1 will be the interface between AT and thrombin&lt;br /&gt;
Green scene 2 will be the the interface structure plus heparin&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923545</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923545"/>
		<updated>2014-05-05T17:47:08Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
This is a default text for your page &#039;&#039;&#039;Yunlong Zhao/Sandbox 1&#039;&#039;&#039;. Click above on &#039;&#039;&#039;edit this page&#039;&#039;&#039; to modify. Be careful with the &amp;amp;lt; and &amp;amp;gt; signs.&lt;br /&gt;
You may include any references to papers as in: the use of JSmol in Proteopedia &amp;lt;ref&amp;gt;DOI 10.1002/ijch.201300024&amp;lt;/ref&amp;gt; or to the article describing Jmol &amp;lt;ref&amp;gt;PMID:21638687&amp;lt;/ref&amp;gt; to the rescue.&amp;lt;ref&amp;gt;DOI 10.1021/bi034524y&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== Function ==&lt;br /&gt;
&lt;br /&gt;
== Disease ==&lt;br /&gt;
&lt;br /&gt;
== Relevance ==&lt;br /&gt;
&lt;br /&gt;
== Structural highlights ==&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923544</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923544"/>
		<updated>2014-05-05T17:16:55Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Introduction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
This is a default text for your page &#039;&#039;&#039;Yunlong Zhao/Sandbox 1&#039;&#039;&#039;. Click above on &#039;&#039;&#039;edit this page&#039;&#039;&#039; to modify. Be careful with the &amp;amp;lt; and &amp;amp;gt; signs.&lt;br /&gt;
You may include any references to papers as in: the use of JSmol in Proteopedia &amp;lt;ref&amp;gt;DOI 10.1002/ijch.201300024&amp;lt;/ref&amp;gt; or to the article describing Jmol &amp;lt;ref&amp;gt;PMID:21638687&amp;lt;/ref&amp;gt; to the rescue.&lt;br /&gt;
&lt;br /&gt;
== Function ==&lt;br /&gt;
&lt;br /&gt;
== Disease ==&lt;br /&gt;
&lt;br /&gt;
== Relevance ==&lt;br /&gt;
&lt;br /&gt;
== Structural highlights ==&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923543</id>
		<title>User:Yunlong Zhao/Sandbox 1</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao/Sandbox_1&amp;diff=1923543"/>
		<updated>2014-05-05T17:16:03Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: New page: ==Heparin antithrombin interaction== &amp;lt;StructureSection load=&amp;#039;1stp&amp;#039; size=&amp;#039;340&amp;#039; side=&amp;#039;right&amp;#039; caption=&amp;#039;Caption for this structure&amp;#039; scene=&amp;#039;&amp;#039;&amp;gt; This is a default text for your page &amp;#039;&amp;#039;&amp;#039;Yunlong Zh...&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;==Heparin antithrombin interaction==&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1stp&#039; size=&#039;340&#039; side=&#039;right&#039; caption=&#039;Caption for this structure&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
This is a default text for your page &#039;&#039;&#039;Yunlong Zhao/Sandbox 1&#039;&#039;&#039;. Click above on &#039;&#039;&#039;edit this page&#039;&#039;&#039; to modify. Be careful with the &amp;amp;lt; and &amp;amp;gt; signs.&lt;br /&gt;
You may include any references to papers as in: the use of JSmol in Proteopedia &amp;lt;ref&amp;gt;DOI 10.1002/ijch.201300024&amp;lt;/ref&amp;gt; or to the article describing Jmol &amp;lt;ref&amp;gt;PMID:21638687&amp;lt;/ref&amp;gt; to the rescue.&lt;br /&gt;
&lt;br /&gt;
== Function ==&lt;br /&gt;
&lt;br /&gt;
== Disease ==&lt;br /&gt;
&lt;br /&gt;
== Relevance ==&lt;br /&gt;
&lt;br /&gt;
== Structural highlights ==&lt;br /&gt;
&lt;br /&gt;
This is a sample scene created with SAT to &amp;lt;scene name=&amp;quot;/12/3456/Sample/1&amp;quot;&amp;gt;color&amp;lt;/scene&amp;gt; by Group, and another to make &amp;lt;scene name=&amp;quot;/12/3456/Sample/2&amp;quot;&amp;gt;a transparent representation&amp;lt;/scene&amp;gt; of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;&lt;br /&gt;
== References ==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=User:Yunlong_Zhao&amp;diff=1923542</id>
		<title>User:Yunlong Zhao</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=User:Yunlong_Zhao&amp;diff=1923542"/>
		<updated>2014-05-05T16:58:18Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;CBI program, University of Massachusetts, Amherst&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1635013</id>
		<title>Sandbox/ caspase-3 regulation</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1635013"/>
		<updated>2012-12-13T17:45:29Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;===Exosite and Allosteric Site===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;StructureSection load=&#039;3ITN&#039; size=&#039;350&#039; side=&#039;right&#039; caption=&#039;Structure of caspase-3 V266E&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Anything in this section will appear adjacent to the 3D structure and will be scrollable.&lt;br /&gt;
&lt;br /&gt;
Caspases have similar structure of active site. Exosite that could be utilized to improve activity has been found in caspase-7 (Boucher, Blais et al. 2012). Caspase-7 also has an inhibitory allosteric site that could bind with small molecule FICA, presenting a zymogen-like conformation (Hardy, Lam et al. 2004).&lt;br /&gt;
&lt;br /&gt;
Although there is no evident exosite found in caspase-3, some allosteric sites, (most of which are located on the dimer interface,) has been studied by mutagenesis. Some of mutant residues can modulate the activity of caspase-3 or even procaspase-3. The procaspase-3 was detected only little activity because the orientation of ILA (prematured L2 loop) and ILB loop cannot form an active site pocket (Bose, Pop et al. 2003).&lt;br /&gt;
&lt;br /&gt;
V266E is a mutation that improves caspase-3 activity dramatically. Even in the uncleavable procaspase-3 (D5A, D26A, D175A), V266E mutant zymogen is also pseudo-activated (60-fold activity). Interestingly, V266E does not change a lot conformation around active site in the active caspase-3. Based on the crystal structure, L2’ loop is partially disorder at 185’-180’. In the homology model of zymogen caspase-3, the catalytic C163 is buried in the dimer interface. E266, which is longer than V266, could push the ILB to the exposed position to make catalytic part is similar as active caspase-3. This active procaspase-3 cannot be inhibited by endogenous XIAP like normal cleaved caspase-3. So it provides us an option for apoptosis stimuli with intrinsic efficiency.&lt;br /&gt;
&lt;br /&gt;
It was found recently that many other mutant residues on the dimer interface might play an important role on inhibition of caspase-3 through manipulating the hydrogen bond or remote talking across whole dimer. For instance, V266H inhibit caspase-3 activity totally, but the double mutation Y197C/V266H the activity is rescued. Structural evidence demonstrates that H266 clashes with Y197, which prevent R164 insert in the dimer interface, which is indispensable to form correct L2 conformation and catalytic loop bundle. Y197C mutation relieves this clash.  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;    &lt;br /&gt;
&lt;br /&gt;
====Post translational Modification====&lt;br /&gt;
&lt;br /&gt;
S-nitrosylation of cysteine also regulates activity of caspase-3 in response of NO in the cell (Maejima, Adachi et al. 2005). As the previous discovery of nitosylated catalytic cysteine in the other caspases, S-nitrosylation directly inhibits the function of C163 of caspase-3. This kind of regulation is sufficiently strong and is a new anti-cancer pathway. For example, induced NO stress could definitely inhibit the myocardial apoptosis at the treatment of DOX.&lt;br /&gt;
&lt;br /&gt;
Phosphorylation consists in another important signaling pathway in biological system. Caspase-3 can be phosphorylated by many kinases like p38a MAPK, PAK2 and PKCdelta. However the site and function of phosphorylation is still unclear.&lt;br /&gt;
&lt;br /&gt;
====Natural Inhibitors====&lt;br /&gt;
X-linked inhibitor of apoptosis proteins (XIAP) contains the second baculovirus IAP repeat domain (BIR2) targeting caspase-3 and caspase-7.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1I3O&#039; size=&#039;350&#039; side=&#039;right&#039; caption=&#039;Structure of complex of caspase-3 with XIAP-BIR2&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Heterotetramer caspase-3 contains two identical active sites. Each active site binds to one BIR2 domain. See &amp;lt;scene name=&#039;Sandbox/_caspase-3_regulation/Overview/1&#039;&amp;gt;Overview&amp;lt;/scene&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Reference:&lt;br /&gt;
&lt;br /&gt;
Bose, K., C. Pop, et al. (2003). &amp;quot;An uncleavable procaspase-3 mutant has a lower catalytic efficiency but an active site similar to that of mature caspase-3.&amp;quot; Biochemistry 42(42): 12298-12310.&lt;br /&gt;
&lt;br /&gt;
Boucher, D., V. Blais, et al. (2012). &amp;quot;Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis.&amp;quot; Proc Natl Acad Sci U S A 109(15): 5669-5674.&lt;br /&gt;
&lt;br /&gt;
Hardy, J. A., J. Lam, et al. (2004). &amp;quot;Discovery of an allosteric site in the caspases.&amp;quot; Proc Natl Acad Sci U S A 101(34): 12461-12466.&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1635011</id>
		<title>Sandbox/ caspase-3 regulation</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1635011"/>
		<updated>2012-12-13T17:23:59Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;===Exosite and Allosteric Site===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;StructureSection load=&#039;3ITN&#039; size=&#039;350&#039; side=&#039;right&#039; caption=&#039;Structure of caspase-3 V266E&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Anything in this section will appear adjacent to the 3D structure and will be scrollable.&lt;br /&gt;
&lt;br /&gt;
Caspases have similar structure of active site. Exosite that could be utilized to improve activity has been found in caspase-7 (Boucher, Blais et al. 2012). Caspase-7 also has an inhibitory allosteric site that could bind with small molecule FICA, presenting a zymogen-like conformation (Hardy, Lam et al. 2004).&lt;br /&gt;
&lt;br /&gt;
Although there is no evident exosite found in caspase-3, some allosteric sites, (most of which are located on the dimer interface,) has been studied by mutagenesis. Some of mutant residues can modulate the activity of caspase-3 or even procaspase-3. The procaspase-3 was detected only little activity because the orientation of ILA (prematured L2 loop) and ILB loop cannot form an active site pocket (Bose, Pop et al. 2003).&lt;br /&gt;
&lt;br /&gt;
V266E is a mutation that improves caspase-3 activity dramatically. Even in the uncleavable procaspase-3 (D5A, D26A, D175A), V266E mutant zymogen is also pseudo-activated (60-fold activity). Interestingly, V266E does not change a lot conformation around active site in the active caspase-3. Based on the crystal structure, L2’ loop is partially disorder at 185’-180’. In the homology model of zymogen caspase-3, the catalytic C163 is buried in the dimer interface. E266, which is longer than V266, could push the ILB to the exposed position to make catalytic part is similar as active caspase-3. This active procaspase-3 cannot be inhibited by endogenous XIAP like normal cleaved caspase-3. So it provides us an option for apoptosis stimuli with intrinsic efficiency.&lt;br /&gt;
&lt;br /&gt;
It was found recently that many other mutant residues on the dimer interface might play an important role on inhibition of caspase-3 through manipulating the hydrogen bond or remote talking across whole dimer. For instance, V266H inhibit caspase-3 activity totally, but the double mutation Y197C/V266H the activity is rescued. Structural evidence demonstrates that H266 clashes with Y197, which prevent R164 insert in the dimer interface, which is indispensable to form correct L2 conformation and catalytic loop bundle. Y197C mutation relieves this clash.  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;    &lt;br /&gt;
&lt;br /&gt;
====Post translational Modification====&lt;br /&gt;
&lt;br /&gt;
S-nitrosylation of cysteine also regulates activity of caspase-3 in response of NO in the cell (Maejima, Adachi et al. 2005). As the previous discovery of nitosylated catalytic cysteine in the other caspases, S-nitrosylation directly inhibits the function of C163 of caspase-3. This kind of regulation is sufficiently strong and is a new anti-cancer pathway. For example, induced NO stress could definitely inhibit the myocardial apoptosis at the treatment of DOX.&lt;br /&gt;
&lt;br /&gt;
Phosphorylation consists in another important signaling pathway in biological system. Caspase-3 can be phosphorylated by many kinases like p38a MAPK, PAK2 and PKCdelta. However the site and function of phosphorylation is still unclear.&lt;br /&gt;
&lt;br /&gt;
====Natural Inhibitors====&lt;br /&gt;
X-linked inhibitor of apoptosis proteins (XIAP) contains the second baculovirus IAP repeat domain (BIR2) targeting caspase-3 and caspase-7.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1I30&#039; size=&#039;350&#039; side=&#039;right&#039; caption=&#039;Structure of complex of caspase-3 with XIAP-BIR2&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt; &lt;br /&gt;
&lt;br /&gt;
Reference:&lt;br /&gt;
&lt;br /&gt;
Bose, K., C. Pop, et al. (2003). &amp;quot;An uncleavable procaspase-3 mutant has a lower catalytic efficiency but an active site similar to that of mature caspase-3.&amp;quot; Biochemistry 42(42): 12298-12310.&lt;br /&gt;
&lt;br /&gt;
Boucher, D., V. Blais, et al. (2012). &amp;quot;Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis.&amp;quot; Proc Natl Acad Sci U S A 109(15): 5669-5674.&lt;br /&gt;
&lt;br /&gt;
Hardy, J. A., J. Lam, et al. (2004). &amp;quot;Discovery of an allosteric site in the caspases.&amp;quot; Proc Natl Acad Sci U S A 101(34): 12461-12466.&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1634843</id>
		<title>Sandbox/ caspase-3 regulation</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1634843"/>
		<updated>2012-12-13T08:35:22Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;===Exosite and Allosteric Site===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;StructureSection load=&#039;3ITN&#039; size=&#039;350&#039; side=&#039;right&#039; caption=&#039;Structure of caspase-3 V266E&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Anything in this section will appear adjacent to the 3D structure and will be scrollable.&lt;br /&gt;
&lt;br /&gt;
Caspases have similar structure of active site. Exosite that could be utilized to improve activity has been found in caspase-7 (Boucher, Blais et al. 2012). Caspase-7 also has an inhibitory allosteric site that could bind with small molecule FICA, presenting a zymogen-like conformation (Hardy, Lam et al. 2004).&lt;br /&gt;
&lt;br /&gt;
Although there is no evident exosite found in caspase-3, some allosteric sites, (most of which are located on the dimer interface,) has been studied by mutagenesis. Some of mutant residues can modulate the activity of caspase-3 or even procaspase-3. The procaspase-3 was detected only little activity because the orientation of ILA (prematured L2 loop) and ILB loop cannot form an active site pocket (Bose, Pop et al. 2003).&lt;br /&gt;
&lt;br /&gt;
V266E is a mutation that improves caspase-3 activity dramatically. Even in the uncleavable procaspase-3 (D5A, D26A, D175A), V266E mutant zymogen is also pseudo-activated (60-fold activity). Interestingly, V266E does not change a lot conformation around active site in the active caspase-3. Based on the crystal structure, L2’ loop is partially disorder at 185’-180’. In the homology model of zymogen caspase-3, the catalytic C163 is buried in the dimer interface. E266, which is longer than V266, could push the ILB to the exposed position to make catalytic part is similar as active caspase-3. This active procaspase-3 cannot be inhibited by endogenous XIAP like normal cleaved caspase-3. So it provides us an option for apoptosis stimuli with intrinsic efficiency.&lt;br /&gt;
&lt;br /&gt;
It was found recently that many other mutant residues on the dimer interface might play an important role on inhibition of caspase-3 through manipulating the hydrogen bond or remote talking across whole dimer. For instance, V266H inhibit caspase-3 activity totally, but the double mutation Y197C/V266H the activity is rescued. Structural evidence demonstrates that H266 clashes with Y197, which prevent R164 insert in the dimer interface, which is indispensable to form correct L2 conformation and catalytic loop bundle. Y197C mutation relieves this clash.  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;    &lt;br /&gt;
&lt;br /&gt;
====Post translational Modification====&lt;br /&gt;
&lt;br /&gt;
S-nitrosylation of cysteine also regulates activity of caspase-3 in response of NO in the cell (Maejima, Adachi et al. 2005). As the previous discovery of nitosylated catalytic cysteine in the other caspases, S-nitrosylation directly inhibits the function of C163 of caspase-3. This kind of regulation is sufficiently strong and is a new anti-cancer pathway. For example, induced NO stress could definitely inhibit the myocardial apoptosis at the treatment of DOX.&lt;br /&gt;
&lt;br /&gt;
====Natural Inhibitors====&lt;br /&gt;
X-linked inhibitor of apoptosis proteins (XIAP) contains the second baculovirus IAP repeat domain (BIR2) targeting caspase-3 and caspase-7.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Reference:&lt;br /&gt;
&lt;br /&gt;
Bose, K., C. Pop, et al. (2003). &amp;quot;An uncleavable procaspase-3 mutant has a lower catalytic efficiency but an active site similar to that of mature caspase-3.&amp;quot; Biochemistry 42(42): 12298-12310.&lt;br /&gt;
&lt;br /&gt;
Boucher, D., V. Blais, et al. (2012). &amp;quot;Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis.&amp;quot; Proc Natl Acad Sci U S A 109(15): 5669-5674.&lt;br /&gt;
&lt;br /&gt;
Hardy, J. A., J. Lam, et al. (2004). &amp;quot;Discovery of an allosteric site in the caspases.&amp;quot; Proc Natl Acad Sci U S A 101(34): 12461-12466.&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1632879</id>
		<title>Sandbox/ caspase-3 regulation</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1632879"/>
		<updated>2012-12-12T21:27:37Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;===Exosite and Allosteric Site===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;StructureSection load=&#039;3ITN&#039; size=&#039;350&#039; side=&#039;right&#039; caption=&#039;Structure of caspase-3 V266E&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Anything in this section will appear adjacent to the 3D structure and will be scrollable.&lt;br /&gt;
&lt;br /&gt;
Caspases have similar structure of active site. Exosite that could be utilized to improve activity has been found in caspase-7 (Boucher, Blais et al. 2012). Caspase-7 also has an inhibitory allosteric site that could bind with small molecule FICA, presenting a zymogen-like conformation (Hardy, Lam et al. 2004).&lt;br /&gt;
&lt;br /&gt;
Although there is no evident exosite found in caspase-3, some allosteric sites, (most of which are located on the dimer interface,) has been studied by mutagenesis. Some of mutant residues can modulate the activity of caspase-3 or even procaspase-3. The procaspase-3 was detected only little activity because the orientation of ILA (prematured L2 loop) and ILB loop cannot form an active site pocket (Bose, Pop et al. 2003).&lt;br /&gt;
&lt;br /&gt;
V266E is a mutation that improves caspase-3 activity dramatically. Even in the uncleavable procaspase-3 (D5A, D26A, D175A), V266E mutant zymogen is also pseudo-activated (60-fold activity). Interestingly, V266E does not change a lot conformation around active site in the active caspase-3. Based on the crystal structure, L2’ loop is partially disorder at 185’-180’. In the homology model of zymogen caspase-3, the catalytic C163 is buried in the dimer interface. E266, which is longer than V266, could push the ILB to the exposed position to make catalytic part is similar as active caspase-3. This active procaspase-3 cannot be inhibited by endogenous XIAP like normal cleaved caspase-3. So it provides us an option for apoptosis stimuli with intrinsic efficiency.&lt;br /&gt;
&lt;br /&gt;
It was found recently that many other mutant residues on the dimer interface might play an important role on inhibition of caspase-3 through manipulating the hydrogen bond or remote talking across whole dimer. For instance, V266H inhibit caspase-3 activity totally, but the double mutation Y197C/V266H the activity is rescued. Structural evidence demonstrates that H266 clashes with Y197, which prevent R164 insert in the dimer interface, which is indispensable to form correct L2 conformation and catalytic loop bundle. Y197C mutation relief this clash.  &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;    &lt;br /&gt;
&lt;br /&gt;
====Post translational Modification====&lt;br /&gt;
&lt;br /&gt;
====Natural Inhibitors====&lt;br /&gt;
X-linked inhibitor of apoptosis proteins (XIAP) contains the second baculovirus IAP repeat domain (BIR2) targeting caspase-3 and caspase-7.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Reference:&lt;br /&gt;
&lt;br /&gt;
Bose, K., C. Pop, et al. (2003). &amp;quot;An uncleavable procaspase-3 mutant has a lower catalytic efficiency but an active site similar to that of mature caspase-3.&amp;quot; Biochemistry 42(42): 12298-12310.&lt;br /&gt;
&lt;br /&gt;
Boucher, D., V. Blais, et al. (2012). &amp;quot;Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis.&amp;quot; Proc Natl Acad Sci U S A 109(15): 5669-5674.&lt;br /&gt;
&lt;br /&gt;
Hardy, J. A., J. Lam, et al. (2004). &amp;quot;Discovery of an allosteric site in the caspases.&amp;quot; Proc Natl Acad Sci U S A 101(34): 12461-12466.&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1631851</id>
		<title>Sandbox/ caspase-3 regulation</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1631851"/>
		<updated>2012-12-12T21:03:17Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;===Exosite and Allosteric Site===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;StructureSection load=&#039;3ITN&#039; size=&#039;350&#039; side=&#039;right&#039; caption=&#039;Structure of caspase-3 V266E&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Anything in this section will appear adjacent to the 3D structure and will be scrollable.&lt;br /&gt;
&lt;br /&gt;
Caspases have similar structure of active site. Exosite that could be utilized to improve activity has been found in caspase-7 (Boucher, Blais et al. 2012). Caspase-7 also has an inhibitory allosteric site that could bind with small molecule FICA, presenting a zymogen-like conformation (Hardy, Lam et al. 2004).&lt;br /&gt;
&lt;br /&gt;
Although there is no evident exosite found in caspase-3, some allosteric sites, (most of which are located on the dimer interface,) has been studied by mutagenesis. Some of mutant residues can modulate the activity of caspase-3 or even procaspase-3. The procaspase-3 was detected only little activity because the orientation of ILA (prematured L2 loop) and ILB loop cannot form an active site pocket (Bose, Pop et al. 2003).&lt;br /&gt;
&lt;br /&gt;
V266E is a mutation that improves caspase-3 activity dramatically. Even in the uncleavable procaspase-3 (D5A, D26A, D175A), V266E mutant zymogen is also pseudo-activated (60-fold activity). Interestingly, V266E does not change a lot conformation around active site in the active caspase-3. Based on the crystal structure, L2’ loop is partially disorder at 185’-180’. This active procaspase-3 cannot be inhibited by endogenous XIAP like normal cleaved caspase-3. So it provides us an option for apoptosis stimuli with intrinsic efficiency.&lt;br /&gt;
&lt;br /&gt;
It was found recently that many other mutant residues on the dimer interface might play an important role on inhibition of caspase-3 through manipulating the hydrogen bond or remote talking across whole dimer. For instance, V266H inhibit caspase-3 activity totally, but the double mutation Y197C/V266H the activity is rescued.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;    &lt;br /&gt;
====Post translational Modification====&lt;br /&gt;
&lt;br /&gt;
====Natural Inhibitors====&lt;br /&gt;
X-linked inhibitor of apoptosis proteins (XIAP) contains the second baculovirus IAP repeat domain (BIR2) targeting caspase-3 and caspase-7.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Reference:&lt;br /&gt;
&lt;br /&gt;
Bose, K., C. Pop, et al. (2003). &amp;quot;An uncleavable procaspase-3 mutant has a lower catalytic efficiency but an active site similar to that of mature caspase-3.&amp;quot; Biochemistry 42(42): 12298-12310.&lt;br /&gt;
&lt;br /&gt;
Boucher, D., V. Blais, et al. (2012). &amp;quot;Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis.&amp;quot; Proc Natl Acad Sci U S A 109(15): 5669-5674.&lt;br /&gt;
&lt;br /&gt;
Hardy, J. A., J. Lam, et al. (2004). &amp;quot;Discovery of an allosteric site in the caspases.&amp;quot; Proc Natl Acad Sci U S A 101(34): 12461-12466.&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
	<entry>
		<id>https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1631839</id>
		<title>Sandbox/ caspase-3 regulation</title>
		<link rel="alternate" type="text/html" href="https://proteopedia.org/index.php?title=Sandbox/_caspase-3_regulation&amp;diff=1631839"/>
		<updated>2012-12-12T20:58:32Z</updated>

		<summary type="html">&lt;p&gt;Yunlong Zhao: New page: ===Exosite and Allosteric Site===   &amp;lt;StructureSection load=&amp;#039;1dq8&amp;#039; size=&amp;#039;350&amp;#039; side=&amp;#039;right&amp;#039; caption=&amp;#039;Structure of HMG-CoA reductase (PDB entry 1dq8)&amp;#039; scene=&amp;#039;&amp;#039;&amp;gt; Anything in this section w...&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;===Exosite and Allosteric Site===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;StructureSection load=&#039;1dq8&#039; size=&#039;350&#039; side=&#039;right&#039; caption=&#039;Structure of HMG-CoA reductase (PDB entry [[1dq8]])&#039; scene=&#039;&#039;&amp;gt;&lt;br /&gt;
Anything in this section will appear adjacent to the 3D structure and will be scrollable.&lt;br /&gt;
&lt;br /&gt;
Caspases have similar structure of active site. Exosite that could be utilized to improve activity has been found in caspase-7 (Boucher, Blais et al. 2012). Caspase-7 also has an inhibitory allosteric site that could bind with small molecule FICA, presenting a zymogen-like conformation (Hardy, Lam et al. 2004).&lt;br /&gt;
&lt;br /&gt;
Although there is no evident exosite found in caspase-3, some allosteric sites, (most of which are located on the dimer interface,) has been studied by mutagenesis. Some of mutant residues can modulate the activity of caspase-3 or even procaspase-3. The procaspase-3 was detected only little activity because the orientation of ILA (prematured L2 loop) and ILB loop cannot form an active site pocket (Bose, Pop et al. 2003).&lt;br /&gt;
&lt;br /&gt;
V266E is a mutation that improves caspase-3 activity dramatically. Even in the uncleavable procaspase-3 (D5A, D26A, D175A), V266E mutant zymogen is also pseudo-activated (60-fold activity). Interestingly, V266E does not change a lot conformation around active site in the active caspase-3. Based on the crystal structure, L2’ loop is partially disorder at 185’-180’. This active procaspase-3 cannot be inhibited by endogenous XIAP like normal cleaved caspase-3. So it provides us an option for apoptosis stimuli with intrinsic efficiency.&lt;br /&gt;
&lt;br /&gt;
It was found recently that many other mutant residues on the dimer interface might play an important role on inhibition of caspase-3 through manipulating the hydrogen bond or remote talking across whole dimer. For instance, V266H inhibit caspase-3 activity totally, but the double mutation Y197C/V266H the activity is rescued.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;/StructureSection&amp;gt;    &lt;br /&gt;
====Post translational Modification====&lt;br /&gt;
&lt;br /&gt;
====Natural Inhibitors====&lt;br /&gt;
X-linked inhibitor of apoptosis proteins (XIAP) contains the second baculovirus IAP repeat domain (BIR2) targeting caspase-3 and caspase-7.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Reference:&lt;br /&gt;
&lt;br /&gt;
Bose, K., C. Pop, et al. (2003). &amp;quot;An uncleavable procaspase-3 mutant has a lower catalytic efficiency but an active site similar to that of mature caspase-3.&amp;quot; Biochemistry 42(42): 12298-12310.&lt;br /&gt;
&lt;br /&gt;
Boucher, D., V. Blais, et al. (2012). &amp;quot;Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis.&amp;quot; Proc Natl Acad Sci U S A 109(15): 5669-5674.&lt;br /&gt;
&lt;br /&gt;
Hardy, J. A., J. Lam, et al. (2004). &amp;quot;Discovery of an allosteric site in the caspases.&amp;quot; Proc Natl Acad Sci U S A 101(34): 12461-12466.&lt;/div&gt;</summary>
		<author><name>Yunlong Zhao</name></author>
	</entry>
</feed>